Xenon Pharmaceuticals Announces Positive Phase 1 Results and Preclinical Data for Acute Pain Candidates XEN1701 and XEN1120

Xenon Pharmaceuticals reported positive Phase 1 results for XEN1701 and new preclinical data for XEN1120, with findings presented in two posters at the International Association for the Study of Pain. The company plans to advance both acute-pain candidates into Phase 2 proof-of-concept studies. The report did not provide financial figures or stock-price impacts.